Featured News

Semenkovich publishes research on mechanisms to improve targeted atherosclerosis therapy 

Clay F. Semenkovich, MD
Semenkovich

On June 15, Clay F. Semenkovich, MD and collaborators had their research titled “Altered Peroxisome Proliferator-Activated Receptor Alpha Signaling in Variably Diseased Peripheral Arterial Segments,” published in “Frontiers in Cardiovascular Medicine.” 

“Peripheral atherosclerosis that accumulates in the extracranial carotid and lower extremity arteries can lead to significant morbidity and mortality. However, atherosclerotic disease progression is often not homogenous and is accelerated by diabetes.”  The study assesses the expression and signaling in min- verses max-diseased peripheral arterial segments. 

Their findings show the significance of “differential expression of ppara and its immediate downstream genes in human carotid and lower extremity arteries relative to disease severity and diabetes.” Including indication that “mechanisms that influence atheroprogression in the carotid and lower extremities peripheral arteries are not homogenous and can be impacted by patient diabetes status and serum cholesterol profiles.” These findings offer insight that can improve targeted atherosclerosis therapy. 

Altered Peroxisome Proliferator-Activated Receptor Alpha Signaling in Variably Diseased Peripheral Arterial Segments